<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8"/>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    <link rel="stylesheet" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/css/bootstrap/bootstrap-grid-modal.css" type="text/css"/>
    <link rel="stylesheet" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/css/style.css" type="text/css"/>
    <link rel="stylesheet" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/css/fonts.css" type="text/css"/>
    <link rel="pingback" href="https://endpts.com/xmlrpc.php">
    <link rel="apple-touch-icon" sizes="180x180" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/apple-touch-icon.png?v=OmJxx0N8zQ">
    <link rel="icon" type="image/png" sizes="32x32" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/favicon-32x32.png?v=OmJxx0N8zQ">
    <link rel="icon" type="image/png" sizes="16x16" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/favicon-16x16.png?v=OmJxx0N8zQ">
    <link rel="manifest" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/site.webmanifest?v=OmJxx0N8zQ">
    <link rel="mask-icon" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/safari-pinned-tab.svg?v=OmJxx0N8zQ" color="#494949">
    <link rel="shortcut icon" href="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/favicon.ico?v=OmJxx0N8zQ">
    <meta name="msapplication-TileColor" content="#bb9451">
    <meta name="msapplication-config" content="https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/favicon/browserconfig.xml?v=OmJxx0N8zQ">
    <meta name="theme-color" content="#ffffff">
    <title>China researchers tout in vitro data for Gilead&#8217;s antiviral against Wuhan virus — which they are trying to patent &#8211; Endpoints News</title>
<link rel='dns-prefetch' href='//www.googletagservices.com' />
<link rel='dns-prefetch' href='//snap.licdn.com' />
<link rel='dns-prefetch' href='//s.w.org' />
<link rel="alternate" type="application/rss+xml" title="Endpoints News &raquo; Feed" href="https://endpts.com/feed/" />
		<script type="text/javascript">
			window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/12.0.0-1\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/12.0.0-1\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/endpts.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=5.4.2"}};
			/*! This file is auto-generated */
			!function(e,a,t){var r,n,o,i,p=a.createElement("canvas"),s=p.getContext&&p.getContext("2d");function c(e,t){var a=String.fromCharCode;s.clearRect(0,0,p.width,p.height),s.fillText(a.apply(this,e),0,0);var r=p.toDataURL();return s.clearRect(0,0,p.width,p.height),s.fillText(a.apply(this,t),0,0),r===p.toDataURL()}function l(e){if(!s||!s.fillText)return!1;switch(s.textBaseline="top",s.font="600 32px Arial",e){case"flag":return!c([127987,65039,8205,9895,65039],[127987,65039,8203,9895,65039])&&(!c([55356,56826,55356,56819],[55356,56826,8203,55356,56819])&&!c([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]));case"emoji":return!c([55357,56424,55356,57342,8205,55358,56605,8205,55357,56424,55356,57340],[55357,56424,55356,57342,8203,55358,56605,8203,55357,56424,55356,57340])}return!1}function d(e){var t=a.createElement("script");t.src=e,t.defer=t.type="text/javascript",a.getElementsByTagName("head")[0].appendChild(t)}for(i=Array("flag","emoji"),t.supports={everything:!0,everythingExceptFlag:!0},o=0;o<i.length;o++)t.supports[i[o]]=l(i[o]),t.supports.everything=t.supports.everything&&t.supports[i[o]],"flag"!==i[o]&&(t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&t.supports[i[o]]);t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&!t.supports.flag,t.DOMReady=!1,t.readyCallback=function(){t.DOMReady=!0},t.supports.everything||(n=function(){t.readyCallback()},a.addEventListener?(a.addEventListener("DOMContentLoaded",n,!1),e.addEventListener("load",n,!1)):(e.attachEvent("onload",n),a.attachEvent("onreadystatechange",function(){"complete"===a.readyState&&t.readyCallback()})),(r=t.source||{}).concatemoji?d(r.concatemoji):r.wpemoji&&r.twemoji&&(d(r.twemoji),d(r.wpemoji)))}(window,document,window._wpemojiSettings);
		</script>
		<style type="text/css">
img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}
</style>
	<link rel='stylesheet' id='EP_css-css'  href='https://endpts.com/wp-content/plugins/endpoints/assets/css/endpoints.css?ver=5.53' type='text/css' media='all' />
<link rel='https://api.w.org/' href='https://endpts.com/wp-json/' />
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://endpts.com/xmlrpc.php?rsd" />
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://endpts.com/wp-includes/wlwmanifest.xml" /> 
<link rel="canonical" href="https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/" />
<link rel='shortlink' href='https://endpts.com/?p=250670' />
<link rel="alternate" type="application/json+oembed" href="https://endpts.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fendpts.com%2Fchina-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent%2F" />
<link rel="alternate" type="text/xml+oembed" href="https://endpts.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fendpts.com%2Fchina-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent%2F&#038;format=xml" />
<meta property="og:image" content="https://endpts.com/wp-content/uploads/2020/01/Coronavirus-scaled.jpg" /><meta property="twitter:image" content="https://endpts.com/wp-content/uploads/2020/01/Coronavirus-scaled.jpg" /><meta property="og:description" content="There’s no definitive proof yet that Gilead’s remdesivir works as a treatment for 2019-nCov, but researchers in China clearly consider it promising enough to have applied for a patent on its use to combat the coronavirus virus outbreak stemming from Wuhan. Amid worldwide vigilance over what many fear is becoming" /><meta property="og:title" content="China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent" /><meta property="og:url" content="https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/" /><meta property="og:site_name" content="Endpoints News" /><meta property="og:type" content="article" /><meta property="article:section" content="Business & Health" /><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content="@endpts"><script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"China researchers tout in vitro data for Gilead's antiviral against Wuhan virus \u2014 which they are trying ...","image":"https:\/\/endpts.com\/wp-content\/uploads\/2020\/01\/Coronavirus-scaled.jpg","url":"https:\/\/endpts.com\/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent\/","copyrightYear":"2020","keywords":"","datePublished":"2020-02-05T12:28:24+00:00","dateModified":"2020-02-05T18:10:02+00:00","author":[{"name":"Amber Tong","jobTitle":"Editor","url":"https:\/\/endpts.com\/author\/amber-tong\/","@type":"Person","image":"https:\/\/endpts.com\/wp-content\/uploads\/2019\/05\/authors-amber.jpg"}],"publisher":{"@type":"Organization","name":"Endpoints News","url":"https:\/\/endpts.com","logo":{"@type":"imageObject","url":"https:\/\/endpts.com\/wp-content\/themes\/endpoints-rakia\/assets\/images\/endpoints_news.png"}},"copyrightHolder":{"@type":"Organization","name":"Endpoints News","url":"https:\/\/endpts.com","logo":{"@type":"imageObject","url":"https:\/\/endpts.com\/wp-content\/themes\/endpoints-rakia\/assets\/images\/endpoints_news.png"}}}</script>    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-66606399-1"></script>
    <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);}
        gtag('js', new Date());
        gtag('config', 'UA-66606399-1');
        _linkedin_partner_id = "2273916";
        window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || [];
        window._linkedin_data_partner_ids.push(_linkedin_partner_id);
    </script>
</head>
<body class="post-template-default single single-post postid-250670">
<header class="epn_header_menu">
    <div class="container">
        <div class="row">
            <div class="col-6 col-md-2">
                <a href="/" class="epn_logo">
                    <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 288 22" style="enable-background:new 0 0 288 22;" xml:space="preserve">
<g>
    <path class="epn_svg_logo" d="M14.69,5.23H5.34v3.64h7.43v4.24H5.34v3.65h9.65v4.6H0V0.63h14.69V5.23z"></path>
    <path class="epn_svg_logo" d="M35.21,12.38h0.21V0.63h5.34v20.73h-3.41L26.18,9.58h-0.21v11.78h-5.34V0.63h3.41L35.21,12.38z"></path>
    <path class="epn_svg_logo" d="M46.8,21.37V0.63h7.35c6.12,0,10.92,4.15,10.92,10.39c0,6.61-4.56,10.35-10.88,10.35H46.8z M54.56,16.77
		c2.91,0,5.05-2.14,5.05-5.83c0-3.57-2.79-5.71-5.09-5.71h-2.38v11.54H54.56z"></path>
    <path class="epn_svg_logo" d="M77.45,14.26h-2.13v7.1h-5.34V0.63h7.63c4.72,0,8.04,2.71,8.04,7.18C85.66,10.61,83.65,14.26,77.45,14.26z
		 M77.04,5.03h-1.72v5.13h1.85c1.64,0,2.79-0.86,2.79-2.46C79.95,6.22,78.84,5.03,77.04,5.03z"></path>
    <path class="epn_svg_logo" d="M100.25,21.78c-6.49,0-11.12-4.68-11.12-10.67c0-6.61,5.34-10.88,11.12-10.88c5.66,0,11.04,4.15,11.04,10.88
		C111.29,16.93,106.94,21.78,100.25,21.78z M100.21,4.9c-2.83,0-5.58,2.22-5.58,6.12c0,3.16,1.93,6.08,5.71,6.08
		c3.04,0,5.5-2.26,5.5-6.08C105.83,7.37,103.25,4.9,100.21,4.9z"></path>
    <path class="epn_svg_logo" d="M121.84,21.37h-5.34V0.63h5.34V21.37z"></path>
    <path class="epn_svg_logo" d="M142.56,12.38h0.21V0.63h5.34v20.73h-3.41L133.53,9.58h-0.21v11.78h-5.34V0.63h3.41L142.56,12.38z"></path>
    <path class="epn_svg_logo" d="M163.91,5.23v16.13h-5.34V5.23h-6.24v-4.6h17.81v4.6H163.91z"></path>
    <path class="epn_svg_logo" d="M174.98,15.09c1.81,1.15,4.23,2.18,6.61,2.18c1.93,0,2.71-0.86,2.71-1.68c0-1.23-1.36-1.72-4.02-2.96
		c-4.19-1.97-5.95-3.49-5.95-6.45s2.5-5.95,7.63-5.95c2.87,0,5.42,0.78,7.31,1.97l-1.23,4.27c-2.09-1.11-4.1-1.72-6.03-1.72
		c-1.56,0-2.26,0.66-2.26,1.44c0,0.86,0.86,1.36,4.06,2.83c4.52,2.09,6.03,3.98,6.03,6.82c0,3.9-3.53,5.95-8.5,5.95
		c-3.57,0-6.61-1.23-7.84-2.38L174.98,15.09z"></path>
    <path class="epn_svg_text" d="M214.24,18.33l0.12-0.08V0.84h1.64v20.53l-0.94,0.21L200.04,3.92l-0.12,0.04v17.41h-1.64V0.84l0.94-0.21
		L214.24,18.33z"></path>
    <path class="epn_svg_text" d="M236.72,2.32h-11.45v7.84h10.22v1.48h-10.22v8.25h11.86v1.48h-13.5V0.84h13.09V2.32z"></path>
    <path class="st0" d="M255.6,4.99l-5.66,16.59h-0.41l-7.96-20.32l1.6-0.62l6.44,16.91h0.21l5.62-16.91h0.41l5.87,16.91h0.21
		l6.16-16.91l1.64,0.62l-7.84,20.32h-0.41l-5.71-16.59H255.6z"></path>
    <path class="epn_svg_text" d="M274.13,17.84c1.56,1.4,3.94,2.42,6.69,2.42c3.94,0,5.46-1.85,5.46-3.86c0-2.14-1.72-3.53-5.38-4.97
		c-4.93-1.89-6.69-3.33-6.69-5.95c0-2.5,2.18-5.05,6.36-5.05c2.87,0,5.58,1.35,6.98,2.67l-0.94,1.23c-1.72-1.4-3.53-2.38-6.03-2.38
		c-3.08,0-4.64,1.6-4.64,3.41c0,1.93,1.15,2.87,5.62,4.64c4.76,1.89,6.44,3.78,6.44,6.36c0,2.92-2.18,5.42-7.22,5.42
		c-3.32,0-6.36-1.31-7.59-2.63L274.13,17.84z"></path>
</g>
</svg>
                </a>
            </div>
            <div class="col-2 d-md-none">
                <a href="#" class="epn_hamburger"><span></span><span></span><span></span></a>
            </div>
            <nav class="col-8 col-md epn_menu_container">
                <div class="epn_menu">
    <ul>
        <li class="menu-item-has-children">
            <span>Channels</span>
            <ul>
                <li><a href="/news/" title="See latest news">All News</a></li>
                <li><a href="/premium" title="Premium Content">Premium Content</a></li>
                <li>
                    <a href="https://endpts.com/channel/coronavirus/" title="See Latest Stories in Coronavirus Channel">Coronavirus</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/rd/" title="See Latest Stories in R&amp;D Channel">R&amp;D</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/pharma/" title="See Latest Stories in Pharma Channel">Pharma</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/venture/" title="See Latest Stories in Venture Channel">Venture</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/people/" title="See Latest Stories in People Channel">People</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/startups/" title="See Latest Stories in Startups Channel">Startups</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/regulatory/" title="See Latest Stories in Regulatory Channel">Regulatory</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/deals/" title="See Latest Stories in Deals Channel">Deals</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/ipos/" title="See Latest Stories in IPOs Channel">IPOs</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/china/" title="See Latest Stories in China Channel">China</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/cell-gene-tx/" title="See Latest Stories in Cell/Gene Tx Channel">Cell/Gene Tx</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/bioregnum/" title="See Latest Stories in Bioregnum Channel">Bioregnum</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/peer-review/" title="See Latest Stories in Peer Review Channel">Peer Review</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/discovery/" title="See Latest Stories in Discovery Channel">Discovery</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/outsourcing/" title="See Latest Stories in Outsourcing Channel">Outsourcing</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/in-focus/" title="See Latest Stories in In Focus">In Focus</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/ai/" title="See Latest Stories in AI Channel">AI</a>
                </li>
                <li>
                    <a href="https://endpts.com/channel/special/" title="See Latest Stories in Special Channel">Special</a>
                </li>
            </ul>
        </li>
       
        <li>
            <a href="https://webinars.endpts.com" title="Endpoints Webinars" target="_blank">Webinars</a>
        </li>        
        <li>
            <a href="https://careers.endpts.com" title="Endpoints Careers" target="_blank">Biopharma Jobs</a>
        </li>
        <li class="menu-item-has-children">
            <span>More</span>
            <ul>
                <li><a href="https://webinars.endpts.com/" target="_blank" title="Endpoints Webinars">Webinars</a></li>
                <li><a href="https://mediakit.endpts.com/events" title="Endpoints Events" target="_blank">Events</a></li>
                <li><a href="https://endpts.com/sponsored/" title="See all Sponsored Posts">Sponsored Posts</a></li>
                <li><a href="https://endpts.com/channel/biotech-voices/" title="Biotech Voices">Biotech Voices</a></li>
                <li><a href="https://mediakit.endpts.com" target="_blank" title="Endpoints News Media Kit">Advertise</a>
                </li>
                <li>
                    <a href="https://www.iubenda.com/privacy-policy/286978" rel="nofollow noopener" target="_blank">Privacy Policy</a>
                </li>
                <li><a href="https://endpts.com/about-endpoints-news/" title="About Endpoints News">About Us</a></li>
                <li><span data-intercom-open >Help</span></li>
            </ul>
        </li>
    </ul>
    <div class="epn_search_bar">
        <form action="https://endpts.com/">
            <input type="text" name="s" placeholder="Search">
            <button class="epn_ux_button epn_white epn_search_submit_button"></button>
        </form>
        <button class="epn_ux_button epn_white epn_search_button"></button>
    </div>
</div>
            </nav>
            <div class="col-8 col-md-2 epn_profile">
    <div class="epn_user epn_logged_out">
        <ul>
            <li><a href="https://endpts.com/subscribe/" title="Subscribe to Endpoints News">SUBSCRIBE</a></li>
            <li>
                <button data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
            </li>
        </ul>
    </div>
</div>
        </div>
    </div>
</header><section class="epn_ad_wrapper epn_regular_section epn_ads_full_width"><div class="container"><div class="row"><div class="col-8"><div id="rakia_above_articles" data-slot="/21729248569/rakia_banner_above_articles"></div></div></div></div></section><section class="sidebar_limit"></section>
<section class="epn_article_body epn_regular_section infinite-scroll epn_body_next_to_sidebar">
    <div class="container">
        <div class="row">
            <div class="col-8 col-md-6 epn_is_stream">
                <article class="epn_regular_section epn_white_box " data-aid="NelweUHm">
    
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/&title=China%20researchers%20tout%20in%20vitro%20data%20for%20Gilead%27s%20antiviral%20against%20Wuhan%20virus%20%E2%80%94%20which%20they%20are%20trying%20to%20patent&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=China%20researchers%20tout%20in%20vitro%20data%20for%20Gilead%27s%20antiviral%20against%20Wuhan%20virus%20%E2%80%94%20which%20they%20are%20trying%20to%20patent - https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">February 5, 2020 07:28 AM EST<span class="epn_time_updated">Updated 01:10 PM</span></div>
    <div class="epn_channel channel-china"><a href="https://endpts.com/channel/china/" title="Channel: China"><span>China</span></a></div>
</div>
        
        <h2>Chi&shy;na re&shy;searchers tout in vit&shy;ro da&shy;ta for Gilead&shy;'s an&shy;tivi&shy;ral against Wuhan virus — which they are try&shy;ing to patent</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-amber.jpg');"></div>
    <div class="epn_text">
        <h3>Amber Tong</h3>
        <h4>Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>There&rsquo;s no de&shy;fin&shy;i&shy;tive proof yet that <a href="https://endpts.com/gsk-pitches-in-on-the-global-rd-campaign-to-develop-a-vaccine-to-counter-a-likely-coronavirus-pandemic/">Gilead&rsquo;s remde&shy;sivir</a> works as a treat&shy;ment for 2019-nCov, but re&shy;searchers in Chi&shy;na clear&shy;ly con&shy;sid&shy;er it promis&shy;ing enough to have ap&shy;plied for a patent on its use to com&shy;bat the coro&shy;n&shy;avirus virus out&shy;break stem&shy;ming from Wuhan.</p>
<p>Amid world&shy;wide vig&shy;i&shy;lance over what many fear is be&shy;com&shy;ing a pan&shy;dem&shy;ic, sci&shy;en&shy;tists from the Wuhan In&shy;sti&shy;tute of Vi&shy;rol&shy;o&shy;gy and Na&shy;tion&shy;al En&shy;gi&shy;neer&shy;ing Re&shy;search Cen&shy;ter for the Emer&shy;gency Drug said they have test&shy;ed a to&shy;tal of sev&shy;en drugs <em>in vit&shy;ro</em> &mdash; and found remde&shy;sivir and the malar&shy;ia treat&shy;ment chloro&shy;quine most ef&shy;fec&shy;tive against the nov&shy;el coro&shy;n&shy;avirus.</p>
<p>In a <a href="http://www.whiov.cas.cn/kyjz_105338/202002/t20200204_5497136.html" target="_blank" rel="nofollow noopener noreferrer">state&shy;ment</a>, the in&shy;sti&shy;tu&shy;tions al&shy;so dis&shy;closed that they filed a patent ap&shy;pli&shy;ca&shy;tion on Jan&shy;u&shy;ary 21, days be&shy;fore Gilead first an&shy;nounced it&rsquo;s <a href="https://endpts.com/gilead-dusts-off-a-failed-ebola-drug-as-coronavirus-spreads-exelixis-boasts-positive-ph-i-ii-data/">dust&shy;ing off</a> the nu&shy;cle&shy;o&shy;side ana&shy;log &mdash; which failed to make the cut as an Ebo&shy;la drug &mdash; to test against the new virus.</p><div class="epn_ad_wrapper"><div class="epn_article_ad" id="rakia_within_article_4098653554" data-slot="/21729248569/rakia_within_article"></div></div>
<p>While ex&shy;perts have in&shy;di&shy;cat&shy;ed that a patent is un&shy;like&shy;ly to be grant&shy;ed, the move high&shy;lights grow&shy;ing con&shy;fi&shy;dence in remde&shy;sivir in the midst of a glob&shy;al race to hunt an&shy;ti&shy;bod&shy;ies and ther&shy;a&shy;pies for 2019-nCoV, for which there is no ap&shy;proved treat&shy;ment. The high&shy;ly con&shy;ta&shy;gious virus has killed more than 490, most&shy;ly in Chi&shy;na.</p>
<p>The up&shy;date al&shy;so comes as the FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first" target="_blank" rel="nofollow noopener noreferrer">is&shy;sued</a> its first Emer&shy;gency Use Au&shy;tho&shy;riza&shy;tion (EUA) since the De&shy;part&shy;ment of Health and Hu&shy;man Ser&shy;vices de&shy;clared a pub&shy;lic health emer&shy;gency in the US on Jan&shy;u&shy;ary 31. The EUA means that the 2019-nCoV di&shy;ag&shy;nos&shy;tic pan&shy;el that&rsquo;s been in use at CDC labs can now be used at any CDC-qual&shy;i&shy;fied lab across the coun&shy;try.</p>
<p>Gilead &mdash; which has been in a patent <a href="https://endpts.com/gilead-claims-truvada-patents-in-hhs-complaint-are-invalid/">dis&shy;pute</a> with the US gov&shy;ern&shy;ment over its HIV fran&shy;chise &mdash; didn&rsquo;t an&shy;swer di&shy;rect&shy;ly whether it knew about the patent fil&shy;ing be&shy;fore the an&shy;nounce&shy;ment or what it thought about the Chi&shy;nese re&shy;searchers&rsquo; grounds.</p>
<blockquote><p>Gilead in&shy;vent&shy;ed remde&shy;sivir and has patent&shy;ed it in Chi&shy;na, in&shy;clud&shy;ing fil&shy;ing patent ap&shy;pli&shy;ca&shy;tions for use on coro&shy;n&shy;avirus&shy;es. We are aware of re&shy;ports of the Wuhan In&shy;sti&shy;tute for Vi&shy;rol&shy;o&shy;gy&rsquo;s patent ap&shy;pli&shy;ca&shy;tion. Our fo&shy;cus at this time, is on rapid&shy;ly de&shy;ter&shy;min&shy;ing the po&shy;ten&shy;tial for remde&shy;sivir as a treat&shy;ment for 2019-nCoV and ac&shy;cel&shy;er&shy;at&shy;ing man&shy;u&shy;fac&shy;tur&shy;ing in an&shy;tic&shy;i&shy;pa&shy;tion of po&shy;ten&shy;tial fu&shy;ture sup&shy;ply needs.</p></blockquote>
<p>Af&shy;ter US doc&shy;tors <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2001191" target="_blank" rel="nofollow noopener noreferrer">re&shy;port&shy;ed</a> us&shy;ing remde&shy;sivir as part of the reg&shy;i&shy;men for the first do&shy;mes&shy;tic case of 2019-nCoV, Gilead said it&rsquo;s work&shy;ing with Chi&shy;nese au&shy;thor&shy;i&shy;ties to start a ran&shy;dom&shy;ized con&shy;trolled tri&shy;al.</p>
<p>Nine tri&shy;als are al&shy;ready un&shy;der&shy;way to eval&shy;u&shy;ate dif&shy;fer&shy;ent com&shy;bi&shy;na&shy;tions of al&shy;ready ap&shy;proved an&shy;tivi&shy;rals and cor&shy;ti&shy;cos&shy;teroids, Bio&shy;Cen&shy;tu&shy;ry <a href="https://www.biocentury.com/article/304368" target="_blank" rel="nofollow noopener noreferrer">not&shy;ed</a>, in&shy;clud&shy;ing HIV drugs such as <a href="https://endpts.com/abbvie-donates-1m-of-the-hiv-drug-that-china-is-now-using-to-contain-coronavirus-outbreak/">Ab&shy;b&shy;Vie&rsquo;s</a> Kale&shy;tra/Alu&shy;via and Gilead&rsquo;s De&shy;scovy.</p>
<p>Remde&shy;sivir, on the oth&shy;er hand, is an ex&shy;per&shy;i&shy;men&shy;tal com&shy;pound that&rsquo;s been test&shy;ed in hu&shy;man tri&shy;als. In a Q4 earn&shy;ings call, Gilead CEO Daniel O&rsquo;Day in&shy;di&shy;cat&shy;ed that it may be de&shy;ployed as an emer&shy;gency treat&shy;ment. In re&shy;sponse to a ques&shy;tion about man&shy;u&shy;fac&shy;tur&shy;ing prepa&shy;ra&shy;tions in the event that they need to scale up pro&shy;duc&shy;tion quick&shy;ly, he had this to re&shy;port:</p>
<blockquote><p>In terms of man&shy;u&shy;fac&shy;tur&shy;ing, our team has re&shy;al&shy;ly been work&shy;ing night and day, it&rsquo;s been very im&shy;pres&shy;sive to watch this team over the past cou&shy;ple of weeks re&shy;al&shy;ly ramp up to the ex&shy;tent that we can. Our ca&shy;pac&shy;i&shy;ty is go&shy;ing up every day. We&rsquo;re look&shy;ing at all the op&shy;tions we have ex&shy;pect&shy;ing to be pre&shy;pared for what may come.</p>
<p>Ob&shy;vi&shy;ous&shy;ly we are wait&shy;ing for da&shy;ta, both <em>in vit&shy;ro</em> and then in peo&shy;ple to en&shy;sure that the drug ac&shy;tu&shy;al&shy;ly works. And it&rsquo;s im&shy;por&shy;tant just for every&shy;one to keep that in mind that this is still in&shy;ves&shy;ti&shy;ga&shy;tion&shy;al and we are still wait&shy;ing for more da&shy;ta to know. But at risk, we are in&shy;vest&shy;ing pret&shy;ty heav&shy;i&shy;ly to make sure that we&rsquo;re pre&shy;pared as best as we can.</p></blockquote>
<p>Around the same time, some <em>in vit&shy;ro</em> da&shy;ta were be&shy;ing <a href="https://www.nature.com/articles/s41422-020-0282-0" target="_blank" rel="nofollow noopener noreferrer">pub&shy;lished</a> on <em>Na&shy;ture</em> as a let&shy;ter to the ed&shy;i&shy;tor.</p>
<p>&ldquo;No&shy;tably, two com&shy;pounds remde&shy;sivir (EC50&thinsp;=&thinsp;0.77&thinsp;&mu;M; CC50&thinsp;&gt;&thinsp;100&thinsp;&mu;M; SI&thinsp;&gt;&thinsp;129.87) and chloro&shy;quine (EC50&thinsp;=&thinsp;1.13&thinsp;&mu;M; CC50&thinsp;&gt;&thinsp;100&thinsp;&mu;M, SI&thinsp;&gt;&thinsp;88.50) po&shy;tent&shy;ly blocked virus in&shy;fec&shy;tion at low-mi&shy;cro&shy;mo&shy;lar con&shy;cen&shy;tra&shy;tion and showed high SI,&rdquo; they wrote.</p>
<p>Giv&shy;en its po&shy;ten&shy;tial, the Wuhan In&shy;sti&shy;tute of Vi&shy;rol&shy;o&shy;gy said in a state&shy;ment, it&rsquo;s ap&shy;plied for a patent in Chi&shy;na and plans to dis&shy;trib&shy;ute to oth&shy;er coun&shy;tries via the Patent Co&shy;op&shy;er&shy;a&shy;tion Treaty. But should &ldquo;the rel&shy;e&shy;vant over&shy;seas com&shy;pa&shy;ny&rdquo; be will&shy;ing to con&shy;tribute to the out&shy;break con&shy;trol, they would tem&shy;porar&shy;i&shy;ly sus&shy;pend ex&shy;er&shy;cise of their patent rights.</p>
<p>But ex&shy;perts in&shy;ter&shy;viewed by <a href="https://m.21jingji.com/article/20200205/herald/5aff07af6c82edc3d81453b77f6fcae2.html" target="_blank" rel="nofollow noopener noreferrer">lo&shy;cal me&shy;dia</a> point out that the ap&shy;pli&shy;ca&shy;tion may not go through. Not on&shy;ly does Gilead hold the foun&shy;da&shy;tion&shy;al patent to the drug, but it al&shy;so ap&shy;plied for one to cov&shy;er remde&shy;sivir&rsquo;s use in coro&shy;n&shy;avirus&shy;es back in 2016 &mdash; which didn&rsquo;t spec&shy;i&shy;fy but could ar&shy;guably in&shy;clude this new strain.</p>


<div class="epn_tag_box">
    
</div>
<div class="epn_author_box">
    <h3 class="epn_section_title">AUTHOR</h3>
    <div class="single_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-amber.jpg');"></div>
    <div class="epn_text">
        <h3><a href="https://endpts.com/author/amber-tong/" title="See all stories by Amber Tong">Amber Tong</a></h3>
        <h4>Editor</h4>
        <div class="epn_social">
            <div class="epn_left">
                <a href="mailto:amber@endpointsnews.com" class="epn_mail">amber@endpointsnews.com</a>
                <a href="https://twitter.com/AmberTongPW" title="Find Amber Tong on Twitter" rel="nofollow noopener" target="_blank" class="epn_twitter">@AmberTongPW</a>
            </div>
            <div class="epn_right">
                <a href="https://www.linkedin.com/in/amber-pak-wei-tong-5aa385bb/" title="Find Amber Tong on LinkedIn"  rel="nofollow noopener" target="_blank" class="epn_linkedin">Amber Tong on LinkedIn</a>
                
            </div>
        </div>
    </div>
</div>
</div>
        </div>
    </div>
</article>
            <article class="epn_regular_section epn_white_box epn_article_preview" data-aid="Nep3f0Xk">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/07/Tal-Zaks-Moderna-youtube-tile-scaled.jpg">
    <div class="epn_description"><span>Tal Zaks, Moderna CMO (Moderna via YouTube)</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/&title=UPDATED%3A%20NIAID%20and%20Moderna%20spell%20out%20a%20%27robust%27%20immune%20response%20in%20PhI%20coronavirus%20vaccine%20test%20%E2%80%94%20but%20big%20questions%20remain%20to%20be%20answered&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=UPDATED%3A%20NIAID%20and%20Moderna%20spell%20out%20a%20%27robust%27%20immune%20response%20in%20PhI%20coronavirus%20vaccine%20test%20%E2%80%94%20but%20big%20questions%20remain%20to%20be%20answered - https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 14, 2020 05:00 PM EDT<span class="epn_time_updated">Updated July 15, 06:26 AM</span></div>
    <div class="epn_channel channel-rd"><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span></a></div><div class="epn_channel channel-coronavirus"><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span></a></div>
</div>
        
        <h2>UP&shy;DAT&shy;ED: NI&shy;AID and Mod&shy;er&shy;na spell out a 'ro&shy;bust' im&shy;mune re&shy;sponse in PhI coro&shy;n&shy;avirus vac&shy;cine test — but big ques&shy;tions re&shy;main to be an&shy;swered</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-john.jpg');"></div>
    <div class="epn_text">
        <h3>John Carroll</h3>
        <h4>Editor & Founder</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>The NIAID and Moderna have spelled out positive Phase I safety and efficacy data for their Covid-19 vaccine mRNA-1273 &mdash; highlighting the first full, clear sketch of evidence that back-to-back jabs at the dose selected for <a href="https://endpts.com/moderna-burnishes-its-phiii-ready-covid-19-vaccine-with-promising-mouse-data-which-suggest-one-dose-might-be-enough-after-all/">Phase III</a> routinely produced a swarm of antibodies to the virus that exceeded levels seen in convalescent patients &mdash; typically in multiples indicating a protective response.</p>
<p>Moderna execs say plainly that this first stage of research produced exactly the kind of efficacy they hoped to see <a href="https://endpts.com/breaking-moderna-posts-a-promising-snapshot-of-human-data-for-a-leading-covid-19-vaccine/">in humans</a>, with a manageable safety profile.</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
    <h3>Keep reading Endpoints with a free subscription</h3>
    <p> Unlock this story instantly and join 85,400+ biopharma pros reading Endpoints daily &mdash; and it's free.  </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>

        </div>
    </div>
</article><article class="epn_regular_section epn_white_box epn_article_preview epn_article_premium" data-aid="Nep3fkPj">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/07/Tillman-Gerngross-tile-scaled.jpg">
    <div class="epn_description"><span>Tillman Gerngross, Adagio Therapeutics CEO</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/&title=Antibody%20legend%20Tillman%20Gerngross%20is%20elbowing%20his%20way%20into%20the%20Covid-19%20R%26D%20crusade%3A%20%27I%20don%E2%80%99t%20see%20this%20ending%20anytime%20soon%27&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=Antibody%20legend%20Tillman%20Gerngross%20is%20elbowing%20his%20way%20into%20the%20Covid-19%20R%26D%20crusade%3A%20%27I%20don%E2%80%99t%20see%20this%20ending%20anytime%20soon%27 - https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 16, 2020 08:00 AM EDT</div>
    <div class="epn_channel channel-startups"><a href="https://endpts.com/channel/startups/" title="Channel: Startups"><span>Startups</span></a></div><div class="epn_channel channel-bioregnum"><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span></a></div>
</div>
        
        <h2>An&shy;ti&shy;body leg&shy;end Till&shy;man Gern&shy;gross is el&shy;bow&shy;ing his way in&shy;to the Covid-19 R&D cru&shy;sade: 'I don’t see this end&shy;ing any&shy;time soon'</h2>
        
        <div class="epn_content">
            <p>One of the most influential &mdash; and outspoken &mdash; scientists at work in the field of antibody discovery is jumping into the frenzied race to create new therapeutics to treat and prevent Covid-19. And he&rsquo;s operating with the conviction that the current outbreak now once again spreading like wildfire will create plenty of demand for what he has in mind.</p>
<p>Dartmouth professor and Adimab CEO <a href="https://endpts.com/tillman-gerngross-isnt-out-to-impress-you-with-biobucks-but-here-are-3-partner-deals-that-should/">Tillman Gerngross</a> tells me he&rsquo;s raised $50 million from a group of close VCs to spin out a new company &mdash; Adagio Therapeutics &mdash; with a full C-suite team assembled to hire up a staff and keep rolling toward the clinic.</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_premium_logo.svg" alt="Endpoints Premium">
    <h3>Premium subscription required</h3>
    <p>Unlock this article along with other benefits by subscribing to one of our paid plans. </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>
        </div>
    </div>
</article>
<section class="epn_regular_section epn_instream_ad epn_ad_wrapper"><div id="rakia_in_stream_1421276465" data-slot="/21729248569/rakia_instream"></div></section><article class="epn_regular_section epn_white_box " data-aid="Nep3fEPm">
    
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/&title=China%27s%20CRO%20powerhouse%20Tigermed%20to%20seek%20%241B%20IPO%20in%20Hong%20Kong%20%E2%80%94%20report&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=China%27s%20CRO%20powerhouse%20Tigermed%20to%20seek%20%241B%20IPO%20in%20Hong%20Kong%20%E2%80%94%20report - https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 17, 2020 10:44 AM EDT</div>
    <div class="epn_channel channel-ipos"><a href="https://endpts.com/channel/ipos/" title="Channel: IPOs"><span>IPOs</span></a></div><div class="epn_channel channel-china"><a href="https://endpts.com/channel/china/" title="Channel: China"><span>China</span></a></div>
</div>
        
        <h2>Chi&shy;na's CRO pow&shy;er&shy;house Tigermed to seek $1B IPO in Hong Kong — re&shy;port</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-amber.jpg');"></div>
    <div class="epn_text">
        <h3>Amber Tong</h3>
        <h4>Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>Hong Kong&rsquo;s effervescent biopharma IPO market could see its biggest debut of the year yet.</p>
<p>Hangzhou Tigermed, a clinical research service provider that also invests in biotech companies, has been approved for a listing on the HKEX and is looking to raise about $1 billion, <em>Bloomberg</em> <a href="https://www.bloomberg.com/news/articles/2020-07-17/tigermed-is-said-to-get-hkex-greenlight-for-1-billion-listing?sref=PaCdHFfq" target="_blank" rel="nofollow noopener noreferrer">reported</a>. It would be a dual listing for the Shenzhen-listed company.</p>
<p>Through its US-based subsidiary Frontage Holdings, Tigermed has seen first-hand just how much appetite investors have for HKEX healthcare stocks. The company, which began trading last July, is now trading 39% above its debut price.</p>

<div class="epn_more">
    <button type="button" class="epn_ux_button epn_more">Read More</button>
</div>

        </div>
    </div>
</article>
            <article class="epn_regular_section epn_white_box epn_article_full">
    <div class="epn_text">
        <div class="epn_byline epn_underlined">
            <div class="epn_social">
                <span data-link="https://careers.endpts.com/jobs/35986325-director-of-regulatory-affairs-at-recursion" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
                <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://careers.endpts.com/jobs/35986325-director-of-regulatory-affairs-at-recursion&title=Director%20of%20Regulatory%20Affairs%20at%20Recursion%20Pharmaceuticals&source=https://endpts.com/" class="epn_byline_linkedin"></a>
                <a href="https://twitter.com/intent/tweet?text=Director%20of%20Regulatory%20Affairs%20at%20Recursion%20Pharmaceuticals%20-%20https%3A%2F%2Fcareers.endpts.com%2Fjobs%2F35986325-director-of-regulatory-affairs-at-recursion" class="epn_byline_twitter"></a>
            </div>
            <div class="epn_section_title careers_title"><span>ENDPOINTS CAREERS</span></div>
        </div>
        <div class="epn_content">
            <div class="careers_box">
                <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/careers_logo.png');"></div>
                <div class="epn_text">
                    <h3><a href="https://careers.endpts.com/jobs/35986325-director-of-regulatory-affairs-at-recursion" target="_blank">Director of Regulatory Affairs</a></h3>
                    <h4>Recursion Pharmaceuticals</h4>
                    <h4>Salt Lake City, UT</h4>
                    <div>
                        <a href="https://careers.endpts.com/jobs/35986325-director-of-regulatory-affairs-at-recursion" class="epn_ux_button careers_but" target="_blank">view job offer</a>
                        <a href="https://careers.endpts.com/products" rel="nofollow noopener" target="_blank" class="post_job">post your job now</a>
                    </div>
                </div>
            </div>


        </div>
    </div>
</article><article class="epn_regular_section epn_white_box epn_article_preview" data-aid="Nep3fUHm">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/07/Jennifer-Doudna-tile-AP-scaled.jpg">
    <div class="epn_description"><span>Jennifer Doudna, AP Images</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/a-jennifer-doudna-led-team-finds-a-new-crispr-enzyme-in-the-giant-viruses-of-a-california-mud-bog/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/a-jennifer-doudna-led-team-finds-a-new-crispr-enzyme-in-the-giant-viruses-of-a-california-mud-bog/&title=A%20Jennifer%20Doudna-led%20team%20finds%20a%20new%20CRISPR%20enzyme%20in%20the%20giant%20viruses%20of%20a%20California%20mud%20bog&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=A%20Jennifer%20Doudna-led%20team%20finds%20a%20new%20CRISPR%20enzyme%20in%20the%20giant%20viruses%20of%20a%20California%20mud%20bog - https://endpts.com/a-jennifer-doudna-led-team-finds-a-new-crispr-enzyme-in-the-giant-viruses-of-a-california-mud-bog/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 17, 2020 10:09 AM EDT<span class="epn_time_updated">Updated 11:13 AM</span></div>
    <div class="epn_channel channel-rd"><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span></a></div>
</div>
        
        <h2>A Jen&shy;nifer Doud&shy;na-led team finds a new CRISPR en&shy;zyme in the gi&shy;ant virus&shy;es of a Cal&shy;i&shy;for&shy;nia mud bog</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/09/jason-mast.jpg');"></div>
    <div class="epn_text">
        <h3>Jason Mast</h3>
        <h4>Associate Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>A team led by UC Berkeley&rsquo;s Jennifer Doudna has found a new CRISPR enzyme in an unlikely place: Viruses.</p>
<p>CRISPR, the gene-editing system that&rsquo;s unleashed a revolution in biomedical research, was first reverse-engineered from a system bacteria evolved over eons to defend themselves from viruses. So viruses may sound like a strange place for CRISPR to show up. But the pathogens Doudna were studying belonged to a particular kind of viruses that researchers are just uncovering: Huge phages &ndash; massive viruses that feed on bacteria.</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
    <h3>Keep reading Endpoints with a free subscription</h3>
    <p> Unlock this story instantly and join 85,400+ biopharma pros reading Endpoints daily &mdash; and it's free.  </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>

        </div>
    </div>
</article><article class="epn_regular_section epn_white_box epn_article_preview epn_article_premium" data-aid="Nep3fETk">
    
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/&title=Eli%20Lilly%E2%80%99s%20mirikizumab%20joins%20the%20club%20beating%20up%20on%20Cosentyx%20as%20another%20head-to-head%20study%20leaves%20Novartis%E2%80%99%20drug%20in%20the%20dust&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=Eli%20Lilly%E2%80%99s%20mirikizumab%20joins%20the%20club%20beating%20up%20on%20Cosentyx%20as%20another%20head-to-head%20study%20leaves%20Novartis%E2%80%99%20drug%20in%20the%20dust - https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 17, 2020 09:02 AM EDT<span class="epn_time_updated">Updated 09:32 AM</span></div>
    <div class="epn_channel channel-rd"><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span></a></div>
</div>
        
        <h2>Eli Lil&shy;ly’s mirik&shy;izum&shy;ab joins the club beat&shy;ing up on Cosen&shy;tyx as an&shy;oth&shy;er head-to-head study leaves No&shy;var&shy;tis’ drug in the dust</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-john.jpg');"></div>
    <div class="epn_text">
        <h3>John Carroll</h3>
        <h4>Editor & Founder</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>Eli Lilly&rsquo;s high hopes for its IL-23 anti-inflammatory drug mirikizumab were borne out by a successful round of Phase III data demonstrating its superiority to Novartis&rsquo; IL-17 drug Cosentyx for psoriasis. But as is often the case, they&rsquo;ve been beaten to the punch by rivals that have even (slightly) better numbers to boast about.</p>
<p>Looking at the PASI 90 score, a key measure on improvement in skin clearance from baseline, the late-stage drug hit PASI 90 scores of 81.4% and 82.4% at 52 weeks &mdash; compared to a mere 69.4% for the Novartis drug.</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_premium_logo.svg" alt="Endpoints Premium">
    <h3>Premium subscription required</h3>
    <p>Unlock this article along with other benefits by subscribing to one of our paid plans. </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>
        </div>
    </div>
</article>
<section class="epn_regular_section epn_instream_ad epn_ad_wrapper"><div id="rakia_in_stream_1820383549" data-slot="/21729248569/rakia_instream"></div></section><article class="epn_regular_section epn_white_box epn_article_preview" data-aid="Nep3fUHn">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/06/Paul-Hudson-tile-AP-scaled.jpg">
    <div class="epn_description"><span>Paul Hudson, Sanofi CEO (Sipa via AP Images)</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/&title=UPDATED%3A%20Suggested%20by%20Bloomberg%2C%20blessed%20by%20analysts%2C%20could%20an%20M%26A%20match%20with%20a%20certain%20MS%20player%20be%20far%20off%20for%20blockbuster-hungry%20Sanofi%3F&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=UPDATED%3A%20Suggested%20by%20Bloomberg%2C%20blessed%20by%20analysts%2C%20could%20an%20M%26A%20match%20with%20a%20certain%20MS%20player%20be%20far%20off%20for%20blockbuster-hungry%20Sanofi%3F - https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 17, 2020 06:45 AM EDT<span class="epn_time_updated">Updated 10:46 AM</span></div>
    <div class="epn_channel channel-deals"><a href="https://endpts.com/channel/deals/" title="Channel: Deals"><span>Deals</span></a></div>
</div>
        
        <h2>UP&shy;DAT&shy;ED: Sug&shy;gest&shy;ed by Bloomberg, blessed by an&shy;a&shy;lysts, could an M&A match with a cer&shy;tain MS play&shy;er be far off for block&shy;buster-hun&shy;gry Sanofi?</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-john.jpg');"></div>
    <div class="epn_text">
        <h3>John Carroll</h3>
        <h4>Editor & Founder</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>All the signs are right.</p>
<p>Sanofi CEO Paul Hudson has an <a href="https://endpts.com/sanofi-ceo-paul-hudson-has-23b-burning-a-hole-in-his-pocket-and-here-are-some-hints-on-how-he-plans-to-spend-that/">M&amp;A war chest</a> set aside from the sale of their Regeneron stock. A few more strategic deals would add considerable excitement to the late-stage pipeline &mdash; Job 1 at a pharma giant that long ago drifted to the unimpressive side of Big Pharma and desperately wants out. <em>Bloomberg</em> reports that MS and immune disorders are in the crosshairs at the Paris-based multinational.</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
    <h3>Keep reading Endpoints with a free subscription</h3>
    <p> Unlock this story instantly and join 85,400+ biopharma pros reading Endpoints daily &mdash; and it's free.  </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>

        </div>
    </div>
</article><article class="epn_regular_section epn_white_box " data-aid="Nep3f0fl">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/07/woman-women-spotlight-in-biopharma-RD-shutterstock-endpts-tile-scaled.jpg">
    <div class="epn_description"><span>Source: Shutterstock</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/&title=Who%20are%20the%20women%20blazing%20trails%20in%20biopharma%20R%26D%20and%20leading%20the%20fight%20against%20Covid-19%3F%20Nominate%20them%20for%20Endpoints%27%20special%20report&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=Who%20are%20the%20women%20blazing%20trails%20in%20biopharma%20R%26D%20and%20leading%20the%20fight%20against%20Covid-19%3F%20Nominate%20them%20for%20Endpoints%27%20special%20report - https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 15, 2020 09:47 AM EDT</div>
    <div class="epn_channel channel-people"><a href="https://endpts.com/channel/people/" title="Channel: People"><span>People</span></a></div><div class="epn_channel channel-editors-note"><a href="https://endpts.com/channel/editors-note/" title="Channel: Editor's note"><span>Editor's note</span></a></div>
</div>
        
        <h2>Who are the women blaz&shy;ing trails in bio&shy;phar&shy;ma R&D and lead&shy;ing the fight against Covid-19? Nom&shy;i&shy;nate them for End&shy;points' spe&shy;cial re&shy;port</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-amber.jpg');"></div>
    <div class="epn_text">
        <h3>Amber Tong</h3>
        <h4>Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?</p>
<p>It&rsquo;s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&amp;D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.</p>

<div class="epn_more">
    <button type="button" class="epn_ux_button epn_more">Read More</button>
</div>

        </div>
    </div>
</article>
            <article class="epn_regular_section epn_white_box epn_article_full">
    <div class="epn_text">
        <div class="epn_byline epn_underlined">
            <div class="epn_social">
                <span data-link="https://careers.endpts.com/jobs/35876394-head-of-biology-at-orum-therapeutics" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
                <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://careers.endpts.com/jobs/35876394-head-of-biology-at-orum-therapeutics&title=Head%20of%20Biology%20at%20Orum%20Therapeutics&source=https://endpts.com/" class="epn_byline_linkedin"></a>
                <a href="https://twitter.com/intent/tweet?text=Head%20of%20Biology%20at%20Orum%20Therapeutics%20-%20https%3A%2F%2Fcareers.endpts.com%2Fjobs%2F35876394-head-of-biology-at-orum-therapeutics" class="epn_byline_twitter"></a>
            </div>
            <div class="epn_section_title careers_title"><span>ENDPOINTS CAREERS</span></div>
        </div>
        <div class="epn_content">
            <div class="careers_box">
                <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/themes/endpoints-rakia/assets/images/careers_logo.png');"></div>
                <div class="epn_text">
                    <h3><a href="https://careers.endpts.com/jobs/35876394-head-of-biology-at-orum-therapeutics" target="_blank">Head of Biology</a></h3>
                    <h4>Orum Therapeutics</h4>
                    <h4>Cambridge, MA</h4>
                    <div>
                        <a href="https://careers.endpts.com/jobs/35876394-head-of-biology-at-orum-therapeutics" class="epn_ux_button careers_but" target="_blank">view job offer</a>
                        <a href="https://careers.endpts.com/products" rel="nofollow noopener" target="_blank" class="post_job">post your job now</a>
                    </div>
                </div>
            </div>


        </div>
    </div>
</article><article class="epn_regular_section epn_white_box epn_article_preview" data-aid="Nep2dkbu">
    <div class="epn_image">
    <img src="https://endpts.com/wp-content/uploads/2020/07/Jeff-Albers-Blueprint-tile-scaled.jpg">
    <div class="epn_description"><span>Jeff Albers, Blueprint CEO</span></div>
</div>
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/&title=Diagnostic%20champ%20Roche%20buys%20its%20way%20into%20the%20RET%20title%20fight%20with%20Eli%20Lilly%2C%20paying%20%24775M%20in%20cash%20to%20Blueprint&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=Diagnostic%20champ%20Roche%20buys%20its%20way%20into%20the%20RET%20title%20fight%20with%20Eli%20Lilly%2C%20paying%20%24775M%20in%20cash%20to%20Blueprint - https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 14, 2020 06:01 AM EDT<span class="epn_time_updated">Updated 07:09 AM</span></div>
    <div class="epn_channel channel-deals"><a href="https://endpts.com/channel/deals/" title="Channel: Deals"><span>Deals</span></a></div>
</div>
        
        <h2>Di&shy;ag&shy;nos&shy;tic champ Roche buys its way in&shy;to the RET ti&shy;tle fight with Eli Lil&shy;ly, pay&shy;ing $775M in cash to Blue&shy;print</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/05/authors-amber.jpg');"></div>
    <div class="epn_text">
        <h3>Amber Tong</h3>
        <h4>Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>When Roche spelled out its original $1 billion deal &mdash; $45 million of that upfront &mdash; with Blueprint to discover targeted therapies against immunokinases, the biotech partner&rsquo;s RET program was still preclinical. Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game.</p>
<p>Roche gains rights to co-develop and co-commercialize the drug, with sole marketing responsibility for places outside the US and China (where CStone has staked its claim).</p>
<div class="epn_limit">
    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
    <h3>Keep reading Endpoints with a free subscription</h3>
    <p> Unlock this story instantly and join 85,400+ biopharma pros reading Endpoints daily &mdash; and it's free.  </p>
    <div class="epn_cta">
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_subscribe_modal">SUBSCRIBE</button>
        <button type="button" class="epn_ux_button epn_more" data-toggle="modal" data-target="#epn_sign_in_modal">SIGN IN</button>
    </div>
</div>

        </div>
    </div>
</article><section class="epn_regular_section epn_instream_ad epn_ad_wrapper"><div id="rakia_in_stream_2906129832" data-slot="/21729248569/rakia_instream"></div></section><article class="epn_regular_section epn_white_box " data-aid="Nep3fELk">
    
    <div class="epn_text">
        <div class="epn_byline">
    <div class="epn_social">
        <span data-link="https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/" data-container="body" data-toggle="popover" data-placement="left" data-content="Copied!" class="epn_byline_share"></span>
        
        <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/&title=J%26J-partnered%20MeiraGTx%20aims%20at%20Biogen%20with%20new%20eye%20gene%20therapy%20data&source=https://endpts.com/" title="Share on LinkedIn" class="epn_byline_linkedin" rel="nofollow noopener" target="_blank"></a>
        <a href="https://twitter.com/intent/tweet?text=J%26J-partnered%20MeiraGTx%20aims%20at%20Biogen%20with%20new%20eye%20gene%20therapy%20data - https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/" title="Share on Twitter" class="epn_byline_twitter" rel="nofollow noopener" target="_blank"></a>
        
    </div>
    
    <div class="epn_time">July 17, 2020 11:00 AM EDT</div>
    <div class="epn_channel channel-rd"><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span></a></div><div class="epn_channel channel-cell-gene-tx"><a href="https://endpts.com/channel/cell-gene-tx/" title="Channel: Cell/Gene Tx"><span>Cell/Gene Tx</span></a></div>
</div>
        
        <h2>J&J-part&shy;nered MeiraGTx aims at Bio&shy;gen with new eye gene ther&shy;a&shy;py da&shy;ta</h2>
        <div class="epn_author_box byline_author">
    <div class="single_byline_author">
    <div class="epn_image" style="background-image: url('https://endpts.com/wp-content/uploads/2019/09/jason-mast.jpg');"></div>
    <div class="epn_text">
        <h3>Jason Mast</h3>
        <h4>Associate Editor</h4>
    </div>
</div>
</div>
        <div class="epn_content">
            <p>Several months after Biogen touted the first proof-of-concept data from its $800 million eye gene therapy, MeiraGTx and J&amp;J are out with their own early data for a rival treatment.</p>
<p>In a small Phase I/II trial for their gene therapy for the degenerative eye disease x-linked&nbsp;retinitis pigmentosa, MeiraGTx found that the 7 patients in the two lowest dose cohorts saw their vision improve on multiple measures for 6 months. The study will provide the basis for the New York biotech to move into a pivotal Phase III for the gene therapy that J&amp;J paid $100 million <a href="https://endpts.com/jj-snags-rights-to-a-gene-therapy-portfolio-from-little-meiragtx-a-spinoff-from-sam-waksals-kadmon/">to get in on</a> last year.</p>

<div class="epn_more">
    <button type="button" class="epn_ux_button epn_more">Read More</button>
</div>

        </div>
    </div>
</article>
            
            </div>
            <div class="col-8 col-md-2">
                <div class="epn_sticky_sidebar">
                    <div class="epn_white_box epn_stream_box">
                        <div class="epn_item epn_sidebar_active">
    <h3 class="epn_headline">
        <a href="https://endpts.com/china-researchers-tout-in-vitro-data-for-gileads-antiviral-against-wuhan-virus-which-they-are-trying-to-patent/" title="China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent" data-is-alink="NelweUHm">Chi&shy;na re&shy;searchers tout in vit&shy;ro da&shy;ta for Gilead&shy;'s an&shy;tivi&shy;ral against Wuhan virus — which they are try&shy;ing to patent</a>
    </h3>
</div><div class="epn_item">
    <h3 class="epn_headline">
        <a href="https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/" title="UPDATED: NIAID and Moderna spell out a 'robust' immune response in PhI coronavirus vaccine test — but big questions remain to be answered" data-is-alink="Nep3f0Xk">UP&shy;DAT&shy;ED: NI&shy;AID and Mod&shy;er&shy;na spell out a 'ro&shy;bust' im&shy;mune re&shy;sponse in PhI coro&shy;n&shy;avirus vac&shy;cine test — but big ques&shy;tions re&shy;main to be an&shy;swered</a>
    </h3>
</div><div class="epn_item">
    <h3 class="epn_headline">
        <a href="https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/" title="Antibody legend Tillman Gerngross is elbowing his way into the Covid-19 R&D crusade: 'I don’t see this ending anytime soon'" data-is-alink="Nep3fkPj">An&shy;ti&shy;body leg&shy;end Till&shy;man Gern&shy;gross is el&shy;bow&shy;ing his way in&shy;to the Covid-19 R&D cru&shy;sade: 'I don’t see this end&shy;ing any&shy;time soon'</a>
    </h3>
</div><div class="epn_item">
    <h3 class="epn_headline">
        <a href="https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/" title="China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report" data-is-alink="Nep3fEPm">Chi&shy;na's CRO pow&shy;er&shy;house Tigermed to seek $1B IPO in Hong Kong — re&shy;port</a>
    </h3>
</div><div class="epn_item">
    <h3 class="epn_headline">
        <a href="https://endpts.com/a-jennifer-doudna-led-team-finds-a-new-crispr-enzyme-in-the-giant-viruses-of-a-california-mud-bog/" title="A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog" data-is-alink="Nep3fUHm">A Jen&shy;nifer Doud&shy;na-led team finds a new CRISPR en&shy;zyme in the gi&shy;ant virus&shy;es of a Cal&shy;i&shy;for&shy;nia mud bog</a>
    </h3>
</div><div class="epn_item epn_hidden">
    <h3 class="epn_headline">
        <a href="https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/" title="Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust" data-is-alink="Nep3fETk">Eli Lil&shy;ly’s mirik&shy;izum&shy;ab joins the club beat&shy;ing up on Cosen&shy;tyx as an&shy;oth&shy;er head-to-head study leaves No&shy;var&shy;tis’ drug in the dust</a>
    </h3>
</div><div class="epn_item epn_hidden">
    <h3 class="epn_headline">
        <a href="https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/" title="UPDATED: Suggested by Bloomberg, blessed by analysts, could an M&A match with a certain MS player be far off for blockbuster-hungry Sanofi?" data-is-alink="Nep3fUHn">UP&shy;DAT&shy;ED: Sug&shy;gest&shy;ed by Bloomberg, blessed by an&shy;a&shy;lysts, could an M&A match with a cer&shy;tain MS play&shy;er be far off for block&shy;buster-hun&shy;gry Sanofi?</a>
    </h3>
</div><div class="epn_item epn_hidden">
    <h3 class="epn_headline">
        <a href="https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/" title="Who are the women blazing trails in biopharma R&D and leading the fight against Covid-19? Nominate them for Endpoints' special report" data-is-alink="Nep3f0fl">Who are the women blaz&shy;ing trails in bio&shy;phar&shy;ma R&D and lead&shy;ing the fight against Covid-19? Nom&shy;i&shy;nate them for End&shy;points' spe&shy;cial re&shy;port</a>
    </h3>
</div><div class="epn_item epn_hidden">
    <h3 class="epn_headline">
        <a href="https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/" title="Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint" data-is-alink="Nep2dkbu">Di&shy;ag&shy;nos&shy;tic champ Roche buys its way in&shy;to the RET ti&shy;tle fight with Eli Lil&shy;ly, pay&shy;ing $775M in cash to Blue&shy;print</a>
    </h3>
</div><div class="epn_item epn_hidden">
    <h3 class="epn_headline">
        <a href="https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/" title="J&J-partnered MeiraGTx aims at Biogen with new eye gene therapy data" data-is-alink="Nep3fELk">J&J-part&shy;nered MeiraGTx aims at Bio&shy;gen with new eye gene ther&shy;a&shy;py da&shy;ta</a>
    </h3>
</div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</section><footer class="epn_footer">
    <div class="container">
        <div class="row">
            <div class="col-8 col-md-2">
                <a href="/" class="epn_logo">

                    <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn-logo-tagline-negative.svg" alt="Endpoints News">
                </a>
                <div class="epn_info">
                    <p>Bioscience &amp; Technology Business Center<br>The University of Kansas<br>Lawrence, Kansas
                    </p>
                </div>
                <div class="epn_social">
                    <a href="https://twitter.com/endpts" rel="nofollow noopener" target="_blank" class="epn_footer_twitter" title="Endpoints on Twitter"></a>
                    <a href="https://www.linkedin.com/company/endpoints" rel="nofollow noopener" target="_blank" class="epn_footer_linkedin" title="Endpoints on LinkedIn"></a>

                </div>
            </div>


            <nav class="col-8 col-md-1">
                <h3>Latest</h3>
                <ul>
                    <li><a href="https://endpts.com/news/" title="Latest news">All News</a></li>
                    <li><a href="https://endpts.com/premium/" title="Premium Content">Premium Content</a></li>
                    <li><a href="https://endpts.com/dont-miss/" title="Don't miss stories">Don't Miss</a></li>
                    

                </ul>
            </nav>

            <nav class="col-8 col-md-2">
                <h3>Channels</h3>
                <ul class="epn_menu_2_columns">
                    <li>
                        <a href="https://endpts.com/channel/coronavirus/" title="See Latest Stories in Coronavirus Channel">Coronavirus</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/rd/" title="See Latest Stories in R&amp;D Channel">R&amp;D</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/pharma/" title="See Latest Stories in Pharma Channel">Pharma</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/venture/" title="See Latest Stories in Venture Channel">Venture</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/people/" title="See Latest Stories in People Channel">People</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/startups/" title="See Latest Stories in Startups Channel">Startups</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/regulatory/" title="See Latest Stories in Regulatory Channel">Regulatory</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/deals/" title="See Latest Stories in Deals Channel">Deals</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/ipos/" title="See Latest Stories in IPOs Channel">IPOs</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/china/" title="See Latest Stories in China Channel">China</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/cell-gene-tx/" title="See Latest Stories in Cell/Gene Tx Channel">Cell/Gene Tx</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/bioregnum/" title="See Latest Stories in Bioregnum Channel">Bioregnum</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/peer-review/" title="See Latest Stories in Peer Review Channel">Peer Review</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/discovery/" title="See Latest Stories in Discovery Channel">Discovery</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/outsourcing/" title="See Latest Stories in Outsourcing Channel">Outsourcing</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/in-focus/" title="See Latest Stories in In Focus">In Focus</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/ai/" title="See Latest Stories in AI Channel">AI</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/channel/special/" title="See Latest Stories in Special Channel">Special</a>
                    </li>
                </ul>
            </nav>
            <nav class="col-8 col-md-1">
                <h3>More</h3>
                <ul>
                    <li><a href="https://mediakit.endpts.com/events" target="_blank" title="Endpoints Media Kit">Events</a></li>
                    <li><a href="https://webinars.endpts.com/" target="_blank" title="Endpoints Webinars">Webinars</a></li>
                    <li><a href="https://endpts.com/sponsored/"  title="See all Sponsored Posts">Sponsored Posts</a></li>
                    <li>
                        <a href="https://endpts.com/channel/biotech-voices/" title="Biotech Voices">Biotech Voices</a>
                    </li>
                    <li>
                        <a href="https://mediakit.endpts.com" target="_blank" title="Endpoints News Media Kit">Advertise</a>
                    </li>
                    <li>
                        <a href="https://endpts.com/about-endpoints-news/" title="About Endpoints News">About Us</a>
                    </li>
                    <li>
                        <span data-intercom-open  >Help</span>
                    </li>
                </ul>
            </nav>
            <nav class="col-8 col-md-2">
                <h3>Work in biotech</h3>
                <ul>
                    <li><a href="https://careers.endpts.com" title="Endpoints Careers">Endpoints Careers</a></li>
                </ul>
            </nav>
        </div>
        <div class="row epn_copyright">
            <div class="col-8 col-md  -2">
                <p>© Endpoints Company 2020</p>
            </div>
            <nav class="col-8 col-md-6">
                <ul>
                    
                    <li>
                        <span data-intercom-open  >Help</span>
                    </li>

                    <li>
                        <a href="https://mediakit.endpts.com" target="_blank">Advertise</a>
                    </li>
                    <li>
                        <a href="https://www.iubenda.com/privacy-policy/286978" rel="nofollow noopener" target="_blank">Privacy Policy</a>
                    </li>
                    

                    <li>
                        <a href="https://endpts.com/an-update-on-the-endpoints-business-model-and-how-your-company-can-directly-support-it/">Business Model</a>
                    </li>
                </ul>
            </nav>
        </div>
    </div>
</footer><div class="modal epn_form epn_hidden_soft" tabindex="-1" role="dialog" id="epn_sign_in_modal" aria-hidden="true">
    <div class="modal-dialog modal-dialog-centered" role="document">
        <div class="modal-content">
            <div class="epn_overlay epn_hidden_soft">
                <div class="epn_loader_spinner epn_solid_gold epn_inside_overlay"></div>
            </div>
            <div class="modal-header">
                <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
                <button class="epn_form_close" data-dismiss="modal"></button>
            </div>
            <div class="modal-body">
                <div class="container-fluid">
                    <div class="row">
                        <div class="col-8">
                            <fieldset class="epn_form_content">
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_golden">Sign in to your account</span>
                                </h3>
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_svg ux_envelope"></span>
                                    <span>e-mail</span>
                                </h3>
                                <div class="epn_ux_input epn_no_grey_background">
                                    <input type="email" id="epn_sign_in_modal_email" placeholder="E-mail" data-toggle="tooltip" data-placement="top" title="">
                                </div>
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_svg ux_https"></span>
                                    <span>password</span>
                                </h3>
                                <div class="epn_ux_password ">
                                    <button class="epn_ux_show_password">
                                        <span class="epn_svg ux_eye"></span>
                                        <span class="epn_svg ux_eye_not"></span>
                                    </button>
                                    <div class="epn_ux_input epn_no_grey_background">
                                        <input type="password" id="epn_sign_in_modal_password" placeholder="Password" data-toggle="tooltip" data-placement="top" title="">
                                    </div>
                                </div>
                                <div class="epn_group epn_form_footer">
                                    <div class="epn_half">
                                        <button class="epn_form_link epn_form_opener" data-form="epn_reset_password_modal">Change my password</button>
                                        <button class="epn_form_link epn_form_opener" data-form="epn_request_magic_link_modal">Get a magic email link</button>
                                    </div>
                                    <div class="epn_half epn_align_right">
                                        <button class="epn_ux_button" id="epn_sign_in_modal_submit">SIGN IN</button>
                                    </div>
                                </div>
                            </fieldset>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
<div class="modal epn_form epn_hidden_soft" tabindex="-1" role="dialog" id="epn_request_magic_link_modal" aria-hidden="true">
    <div class="modal-dialog modal-dialog-centered" role="document">
        <div class="modal-content">
            <div class="epn_overlay epn_hidden_soft">
                <div class="epn_loader_spinner epn_solid_gold epn_inside_overlay"></div>
            </div>
            <div class="modal-header">
                <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
                <button class="epn_form_close" data-dismiss="modal"></button>
            </div>
            <div class="modal-body">
                <div class="container-fluid">
                    <div class="row">
                        <div class="col-8">
                            <fieldset class="epn_form_content">
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_golden">request magic link</span>
                                </h3>
                                <p>If you're already an Endpoints subscriber, enter your email below for a <b>magic link that lets you sign in quickly without using a password</b>. Please note the magic link is <b>one-time use only</b> and expires after 24 hours.</p>
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_svg ux_envelope"></span>
                                    <span>email</span>
                                </h3>
                                <div class="epn_ux_input epn_no_grey_background">
                                    <input type="email" id="epn_request_magic_link_email" placeholder="E-mail" data-toggle="tooltip" data-placement="top" title="">
                                </div>
                                <div class="epn_group epn_form_footer">
                                    <div class="epn_half">
                                        <button class="epn_ux_button epn_form_opener" data-form="epn_sign_in_modal">BACK</button>
                                    </div>
                                    <div class="epn_half epn_align_right">
                                        <button class="epn_ux_button" id="epn_request_magic_link_submit">REQUEST</button>
                                    </div>
                                </div>
                            </fieldset>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
<div class="modal epn_form epn_hidden_soft" tabindex="-1" role="dialog" id="epn_reset_password_modal" aria-hidden ="true">
    <div class="modal-dialog modal-dialog-centered" role="document">
        <div class="modal-content">
            <div class="epn_overlay epn_hidden_soft">
                <div class="epn_loader_spinner epn_solid_gold epn_inside_overlay"></div>
            </div>
            <div class="modal-header">
                <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
                <button class="epn_form_close" data-dismiss="modal"></button>
            </div>
            <div class="modal-body">
                <div class="container-fluid">
                    <div class="row">
                        <div class="col-8">
                            <fieldset class="epn_form_content">
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_golden">reset password</span>
                                </h3>
                                <p>We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.</p>
                                <h3 class="epn_ux_modal_caption">
                                    <span class="epn_svg ux_envelope"></span>
                                    <span>email</span>
                                </h3>
                                <div class="epn_ux_input epn_no_grey_background">
                                    <input type="email" id="epn_reset_password_email" placeholder="E-mail" data-toggle="tooltip" data-placement="top" title="">
                                </div>
                                <div class="epn_group epn_form_footer">
                                    <div class="epn_half">
                                        <button class="epn_ux_button epn_form_opener" data-form="epn_sign_in_modal">BACK</button>
                                    </div>
                                    <div class="epn_half epn_align_right">
                                        <button class="epn_ux_button" id="epn_reset_password_submit">RESET</button>
                                    </div>
                                </div>
                            </fieldset>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
<div class="modal epn_form" tabindex="-1" role="dialog" id="epn_subscribe_modal" aria-hidden="true">
    <div class="modal-dialog modal-dialog-centered" role="document">
        <div class="modal-content">
            <div class="epn_overlay epn_hidden_soft">
            </div>
            <div class="modal-header">
                <img src="https://endpts.com/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg" alt="Endpoints News">
                <button class="epn_form_close" data-dismiss="modal"></button>
            </div>
            <div class="modal-body">
                <div class="container-fluid">
                    <div class="row">
                        <div class="col-8">
                            <div class="epn_form_content">
                                <h3 class="epn_ux_caption">
                                    <span>About You</span>
                                </h3>
                                <fieldset>
                                    <div class="epn_ux_input">
                                        <input type="email" id="epn_modal_subscribe_email" placeholder="E-mail" data-toggle="tooltip" data-placement="top" title="">
                                    </div>

                                    <div class="epn_ux_input">
                                        <input type="text" id="epn_modal_subscribe_name" placeholder="Full Name" data-toggle="tooltip" data-placement="top" title="">
                                    </div>

                                    <div class="epn_ux_input">
                                        <input type="text" id="epn_modal_subscribe_company" placeholder="Company" data-toggle="tooltip" data-placement="top" title="">
                                    </div>

                                    <div class="epn_ux_input">
                                        <input type="text" id="epn_modal_subscribe_job_title" placeholder="Job Title" data-toggle="tooltip" data-placement="top" title="">
                                    </div>
                                </fieldset>
                                <h3 class="epn_ux_caption">
                                    <span>Subscriptions</span>
                                </h3>
                                <fieldset>
                                    <div class="epn_ux_switch_group epn_white_box">
                                        <p>
                                            <span class="epn_modal_subscribe_bold_uppercase">ENDPOINTS </span><span class="epn_grey">by John Carroll &amp; team — <em>all</em> the news at 11:30a ET</span>
                                        </p>
                                        <div class="epn_ux_switch">
                                            <input type="checkbox" id="epn_modal_subscribe_endpoints_edition" checked="">
                                            <label for="epn_modal_subscribe_endpoints_edition"></label>
                                        </div>
                                    </div>
                                    <div class="epn_ux_switch_group epn_white_box">
                                        <p>
                                            <span class="epn_modal_subscribe_bold_uppercase">EARLY EDITION</span><span class="epn_grey">by Arsalan Arif — skimmable links and news at 7:15a ET </span>
                                        </p>
                                        <div class="epn_ux_switch">
                                            <input type="checkbox" id="epn_modal_subscribe_early_edition" checked="">
                                            <label for="epn_modal_subscribe_early_edition"></label>
                                        </div>
                                    </div>
                                </fieldset>
                                <div class="epn_group">
                                    <button class="epn_ux_button epn_has_tooltip no_tooltip_on_hover" id="epn_modal_subscribe_submit" data-toggle="tooltip" data-placement="top">INSTANT SUBSCRIBE</button>
                                    
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
<script type='text/javascript' src='https://endpts.com/wp-content/themes/endpoints-rakia/assets/js/jquery-3.4.1.min.js?ver=3.4.1'></script>
<script type='text/javascript'>
/* <![CDATA[ */
var isa = {"or":"1595024497","tp":"sa","ajax_url":"https:\/\/endpts.com\/wp-admin\/admin-ajax.php","hashes":["NelweUHm","Nep3f0Xk","Nep3fkPj","Nep3fEPm","Nep3fUHm","Nep3fETk","Nep3fUHn","Nep3f0fl","Nep2dkbu","Nep3fELk"],"ca":"NelweUHm","lj":"Nep2fUbl","ads":["rakia_in_stream_1421276465","rakia_in_stream_1820383549","rakia_in_stream_2906129832"]};
/* ]]> */
</script>
<script type='text/javascript' src='https://endpts.com/wp-content/themes/endpoints-rakia/assets/js/infinite_scroll.js?ver=1.1.4'></script>
<script type='text/javascript' src='https://endpts.com/wp-content/themes/endpoints-rakia/assets/js/script.js?ver=1.1.4'></script>
<script type='text/javascript' src='https://endpts.com/wp-content/themes/endpoints-rakia/assets/js/ca_animator.0.1.9.js?ver=1.1.4'></script>
<script type='text/javascript' src='https://endpts.com/wp-content/themes/endpoints-rakia/assets/js/bootstrap.bundle.min.js?ver=1.1.4'></script>
<script type='text/javascript'>
/* <![CDATA[ */
var ad_units_data = {"\/21729248569\/rakia_banner_above_articles":{"div":"rakia_above_articles","sizes":[[970,250],[340,120],[340,150],[340,200],[720,120],[720,150],[720,200],[1200,150],[1200,200],[1200,250]]},"\/21729248569\/rakia_banner_above_tiles_homepage":{"div":"rakia_above_tiles","sizes":[[970,250],[340,120],[340,150],[340,200],[720,120],[720,150],[720,200],[1200,150],[1200,200],[1200,250]]},"\/21729248569\/rakia_banner_below_tiles_homepage":{"div":"rakia_below_tiles","sizes":[[970,250],[340,120],[340,150],[340,200],[720,120],[720,150],[720,200],[1200,150],[1200,200],[1200,250]]},"\/21729248569\/rakia_within_article":{"div":"rakia_within_article","sizes":[[340,150],[340,200],[340,250],[440,150],[440,190],[440,200],[760,150],[760,200],[760,250]]},"\/21729248569\/rakia_instream":{"div":"rakia_in_stream","sizes":[[340,150],[340,200],[340,250],[520,150],[520,200],[520,220],[890,150],[890,200],[890,250]]},"\/21729248569\/rakia_sponsored_front_page":{"div":"rakia_sponsored_front_page","sizes":[[340,570],[340,595],[592,305]]},"\/21729248569\/rakia_banner_above_tiles_channels":{"div":"rakia_above_tiles_channel","sizes":[[970,250],[340,120],[340,150],[340,200],[720,120],[720,150],[720,200],[1200,150],[1200,200],[1200,250]]},"\/21729248569\/rakia_banner_below_tiles_channels":{"div":"rakia_below_tiles_channel","sizes":[[970,250],[340,120],[340,150],[340,200],[720,120],[720,150],[720,200],[1200,150],[1200,200],[1200,250]]},"\/21729248569\/rakia_inarticle_adx":{"div":"rakia_within_article_adx","sizes":[[300,100],[300,250],[320,100],[336,280],[468,60],[728,90]]},"\/21729248569\/rakia_instream_adx":{"div":"rakia_in_stream_adx","sizes":[[300,100],[300,250],[320,100],[336,280],[468,60],[728,90]]},"isadx":"<section class=\"epn_regular_section epn_instream_ad epn_ad_wrapper\"><div id=\"ridis\" data-slot=\"\/21729248569\/rakia_instream_adx\"><\/div><\/section>","iaadx":"<div class=\"epn_ad_wrapper\"><div class=\"epn_article_ad\" id=\"ridia\" data-slot=\"\/21729248569\/rakia_inarticle_adx\"><\/div><\/div>"};
/* ]]> */
</script>
<script type='text/javascript' src='https://www.googletagservices.com/tag/js/gpt.js'></script>
<script type='text/javascript'>
/* <![CDATA[ */
var EP_ajax_object = {"ajax_url":"https:\/\/endpts.com\/wp-admin\/admin-ajax.php","assets":"https:\/\/endpts.com\/wp-content\/plugins\/endpoints\/assets\/","fallback_spinner":"https:\/\/endpts.com\/wp-content\/plugins\/endpoints\/assets\/images\/loading.gif","comment_source":"250670","intercom":"1"};
/* ]]> */
</script>
<script type='text/javascript' src='https://endpts.com/wp-content/plugins/endpoints/assets/js/endpoints.js?ver=5.53'></script>
<script type='text/javascript' src='https://snap.licdn.com/li.lms-analytics/insight.min.js'></script>
<script type='text/javascript' src='https://endpts.com/wp-includes/js/wp-embed.min.js?ver=5.4.2'></script>
</body>
</html>